Evidence map›Paper›PMID 38483786›Full record

ArticleInfection2024

Incidence of invasive infections with Group B streptococcus in adults in Norway 1996-2019: a nationwide registry-based case-control study.

Elise Uggen, Camilla Olaisen, Randi Valsø Lyng, Gunnar Skov Simonsen, Roar Magne Bævre-Jensen, Frode Width Gran, Bjørn Olav Åsvold, Tom Ivar Lund Nilsen, Jan Kristian Damås, Jan Egil Afset

Abstract read
In one paragraph

Article in Infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elise UggenFaculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. eliseu@stud.ntnu.no.ORCID http://orcid.org/0009-0001-9421-985X
Camilla OlaisenDepartment of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.ORCID http://orcid.org/0000-0003-2266-4150
Randi Valsø LyngDepartment of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Gunnar Skov SimonsenDepartment of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.ORCID http://orcid.org/0000-0003-0043-7045
Roar Magne Bævre-JensenDepartment of Medical Microbiology, Vestre Viken Hospital Trust, Drammen, Norway.ORCID http://orcid.org/0000-0001-5972-7181
Frode Width GranDepartment of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Bjørn Olav ÅsvoldHUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Trondheim, Norway.ORCID http://orcid.org/0000-0003-3837-2101
Tom Ivar Lund NilsenDepartment of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.ORCID http://orcid.org/0000-0001-8251-3544
Jan Kristian DamåsMid-Norway Centre of Sepsis Research, Trondheim, Norway.ORCID http://orcid.org/0000-0003-4268-671X
Jan Egil AfsetMid-Norway Centre of Sepsis Research, Trondheim, Norway.ORCID http://orcid.org/0000-0003-2489-4179

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGroup B streptococcus (GBS) colonizes the gastrointestinal and vaginal mucosa in healthy adults, but has also become an increasing cause of invasive infection. The aims of this study were to describe the incidence and factors associated with the occurrence of invasive GBS disease in adults in Norway.

methodsWe performed a nationwide retrospective case-control study of invasive GBS infections during 1996-2019, with two control groups; invasive Group A streptococcal disease (GAS) to control for changes in surveillance and diagnostics, and a second representing the general population.

resultsA total of 3710 GBS episodes were identified. The age-standardized incidence rate increased steadily from 1.10 (95% CI 0.80-1.50) in 1996 to 6.70 (95% CI 5.90-7.50) per 100,000 person-years in 2019. The incidence rate had an average annual increase of 6.44% (95% CI 5.12-7.78). Incidence rates of GAS varied considerably, and there was no evidence of a consistent change over the study period. GBS incidence was highest among adults > 60 years of age. Cardiovascular disease, cancer, and diabetes were the most common comorbid conditions. There was a shift in the distribution of capsular serotypes from three dominant types to more equal distribution among the six most common serotypes.

conclusionsThe incidence of invasive GBS disease in adults increased significantly from 1996 to 2019. The increasing age of the population with accompanying underlying comorbid conditions might contribute to the increasing burden of invasive GBS disease. Interestingly, type 1 diabetes was also associated with the occurrence of invasive GBS disease.

Indexed as

Streptococcal InfectionsStreptococcus agalactiaeAdolescentAdultAgedAged, 80 and overCase-Control StudiesFemaleHumansIncidenceMaleMiddle AgedNorwayRegistriesRetrospective StudiesRisk FactorsGBSGroup B streptococcusIncidenceInvasive diseaseRisk factorsStreptococcus agalactiae

Identifiers

PMID38483786
PMCPMC11499455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.